Substituted hydantoinamides as ADAMTS7 antagonists

US12398120B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• The Broad Institute, Inc. · US

Inventors

• Daniel Meibom · Leverkusen, DE
• Yolanda Cancho Grande · Leverkusen, DE
• Pierre Wasnaire · Mülheim an der Ruhr, DE
• Sarah Anna Liesa Johannes · Düsseldorf, DE
• Kristin BEYER · Hilden, DE
• Till FREUDENBERGER · Velbert, DE
• Damian Brockschnieder · Haan, DE
• Dmitry Zubov · Remscheid, DE
• Dzianis Menshykau · Düsseldorf, DE
• Tanja Krainz · Pittsburgh, US
• Bryan MacDonald · Cambridge, US
• Yi XING · Andover, US
• Nadine Elowe · Cambridge, US
• Guzman Sanchez · Murcia, ES

Key dates

• Filing date: Nov 12, 2020
• Grant date: Aug 26, 2025
• Expiry date: Nov 9, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.